Lbp Am Sa Has $17.52 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX

Key Points

• Lbp Am Sa reduced its stake in Vertex Pharmaceuticals by 26.5% during the 2nd quarter, leaving them with 39,341 shares valued at approximately $17.52 million.
• Vertex Pharmaceuticals reported a positive earnings surprise with earnings per share of $4.52, exceeding analysts' expectations of $4.24.
• Institutional investors own nearly 91% of Vertex Pharmaceuticals, with numerous firms modifying their positions in the stock recently.

Lbp Am Sa decreased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 26.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,341 shares of the pharmaceutical company's stock after selling 14,200 shares during the quarter. Lbp Am Sa's holdings in Vertex Pharmaceuticals were worth $17,515,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of VRTX. Brighton Jones LLC grew its position in shares of Vertex Pharmaceuticals by 15.0% during the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company's stock worth $1,783,000 after buying an additional 579 shares during the period. Fifth Third Wealth Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 49.5% during the 1st quarter. Fifth Third Wealth Advisors LLC now owns 1,834 shares of the pharmaceutical company's stock worth $889,000 after buying an additional 607 shares during the period. 180 Wealth Advisors LLC acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $224,000. NBC Securities Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $167,000. Finally, LVW Advisors LLC grew its position in shares of Vertex Pharmaceuticals by 3.7% during the 1st quarter. LVW Advisors LLC now owns 794 shares of the pharmaceutical company's stock worth $385,000 after buying an additional 28 shares during the period. Institutional investors and hedge funds own 90.96% of the company's stock.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $391.64 on Wednesday. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.88. The firm's 50 day moving average price is $403.17 and its two-hundred day moving average price is $444.73. The firm has a market cap of $100.41 billion, a P/E ratio of 27.99 and a beta of 0.44.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share for the quarter, beating analysts' consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a net margin of 31.86% and a return on equity of 23.91%. The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. During the same quarter in the previous year, the firm posted ($12.83) earnings per share. The business's revenue was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on VRTX shares. Raymond James Financial started coverage on shares of Vertex Pharmaceuticals in a report on Tuesday, September 2nd. They set a "market perform" rating for the company. JPMorgan Chase & Co. boosted their price objective on shares of Vertex Pharmaceuticals from $515.00 to $517.00 and gave the company an "overweight" rating in a report on Monday, July 14th. BMO Capital Markets set a $530.00 price objective on shares of Vertex Pharmaceuticals and gave the company an "outperform" rating in a report on Tuesday, August 5th. Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, September 25th. Finally, UBS Group set a $553.00 price objective on shares of Vertex Pharmaceuticals and gave the company a "buy" rating in a report on Tuesday, August 5th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eleven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $493.81.

Insiders Place Their Bets

In related news, Director Bruce I. Sachs purchased 5,000 shares of the business's stock in a transaction on Wednesday, August 6th. The shares were purchased at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the purchase, the director owned 45,000 shares in the company, valued at $17,535,600. This represents a 12.50% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.20% of the company's stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.